Clinical Trials Browser

Breast Neoplasms, Recurrence

NCT06926868 2026-04-01

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Phase 2/3 Recruiting

500 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04862585 2025-08-20

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Phase 2/3 Completed

130 enrolled 8 charts

Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT01779206 2025-04-08

ADAPT

Phase 2/3 Completed

4,936 enrolled

Breast

Breast Neoplasms

NCT05747794 2024-12-17

AIPAC-003

Phase 2/3 Active not recruiting

849 enrolled

Breast

Breast Neoplasms

NCT05889390 2024-12-03

NeoHTerMa

Phase 2/3 Active not recruiting

71 enrolled

Breast

Hyperthermia, Breast Neoplasms

NCT05189535 2024-01-23

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

Phase 2/3 Completed

66 enrolled

Breast

Breast Neoplasms, Peripheral Nervous System Diseases

NCT02221999 2023-08-29

SHPD002

Phase 2/3 Active not recruiting

250 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03150576 2022-11-14

PARTNER

Phase 2/3 Recruiting

780 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01057069 2022-10-12

neo-TN

Phase 2/3 Active not recruiting

310 enrolled

Breast

Breast Neoplasms

NCT05189067 2022-01-12

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Phase 2/3 Unknown

190 enrolled

Breast

HER2-positive Breast Cancer

NCT04576143 2021-08-12

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Phase 2/3 Recruiting

260 enrolled

Breast

HER2-negative Breast Cancer

NCT03580395 2021-07-09

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Phase 2/3 Unknown

200 enrolled

Breast

Breast Neoplasms

NCT02651610 2017-07-11

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Phase 2/3 Withdrawn

Breast

Breast Neoplasms

NCT01572727 2017-03-09

BELLE-4

Phase 2/3 Completed

416 enrolled 11 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01426880 2016-02-15

GeparSixto

Phase 2/3 Completed

595 enrolled

Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Clinical Trials

OPTIMAL

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

ADAPT

AIPAC-003

NeoHTerMa

"Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"

SHPD002

PARTNER

neo-TN

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

BELLE-4

GeparSixto